|
Harbin Pharmaceutical Group Co., Ltd. (600664.SS) Avaliação DCF
CN | Healthcare | Drug Manufacturers - Specialty & Generic | SHH
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Harbin Pharmaceutical Group Co., Ltd. (600664.SS) Bundle
Como investidor ou analista, essa calculadora (600664Ss) DCF é o seu recurso essencial para uma avaliação precisa. Equipado com dados reais da Harbin Pharmaceutical Group Co., Ltd., você pode ajustar facilmente as previsões e observar imediatamente os efeitos.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11,824.6 | 10,788.5 | 12,802.0 | 13,808.8 | 15,456.6 | 16,604.2 | 17,837.0 | 19,161.3 | 20,584.0 | 22,112.3 |
| Revenue Growth, % | 0 | -8.76 | 18.66 | 7.86 | 11.93 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 |
| EBITDA | 769.5 | -378.7 | 1,067.8 | 1,122.0 | 1,011.2 | 863.6 | 927.7 | 996.6 | 1,070.6 | 1,150.1 |
| EBITDA, % | 6.51 | -3.51 | 8.34 | 8.13 | 6.54 | 5.2 | 5.2 | 5.2 | 5.2 | 5.2 |
| Depreciation | 410.6 | 380.1 | 324.6 | 321.4 | 304.4 | 459.2 | 493.3 | 529.9 | 569.3 | 611.5 |
| Depreciation, % | 3.47 | 3.52 | 2.54 | 2.33 | 1.97 | 2.77 | 2.77 | 2.77 | 2.77 | 2.77 |
| EBIT | 358.9 | -758.8 | 743.3 | 800.6 | 706.8 | 404.4 | 434.4 | 466.7 | 501.3 | 538.6 |
| EBIT, % | 3.04 | -7.03 | 5.81 | 5.8 | 4.57 | 2.44 | 2.44 | 2.44 | 2.44 | 2.44 |
| Total Cash | 675.5 | 897.0 | 1,592.1 | 2,433.5 | 3,060.4 | 2,121.6 | 2,279.1 | 2,448.3 | 2,630.1 | 2,825.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 4,189.1 | 4,702.9 | 4,748.8 | 5,050.8 | 4,960.6 | 6,136.4 | 6,592.0 | 7,081.4 | 7,607.2 | 8,172.0 |
| Account Receivables, % | 35.43 | 43.59 | 37.09 | 36.58 | 32.09 | 36.96 | 36.96 | 36.96 | 36.96 | 36.96 |
| Inventories | 2,026.1 | 1,861.8 | 2,063.8 | 1,804.2 | 1,924.3 | 2,524.7 | 2,712.2 | 2,913.6 | 3,129.9 | 3,362.3 |
| Inventories, % | 17.13 | 17.26 | 16.12 | 13.07 | 12.45 | 15.21 | 15.21 | 15.21 | 15.21 | 15.21 |
| Accounts Payable | 3,722.6 | 3,667.9 | 1,628.1 | 3,509.9 | 3,950.6 | 4,289.7 | 4,608.2 | 4,950.3 | 5,317.9 | 5,712.7 |
| Accounts Payable, % | 31.48 | 34 | 12.72 | 25.42 | 25.56 | 25.83 | 25.83 | 25.83 | 25.83 | 25.83 |
| Capital Expenditure | -39.0 | -118.2 | -76.7 | -89.6 | -86.5 | -107.4 | -115.4 | -123.9 | -133.1 | -143.0 |
| Capital Expenditure, % | -0.32982 | -1.1 | -0.5991 | -0.64919 | -0.55986 | -0.64674 | -0.64674 | -0.64674 | -0.64674 | -0.64674 |
| Tax Rate, % | 39.24 | 39.24 | 39.24 | 39.24 | 39.24 | 39.24 | 39.24 | 39.24 | 39.24 | 39.24 |
| EBITAT | 142.5 | -818.9 | 437.4 | 531.1 | 429.4 | 263.4 | 282.9 | 304.0 | 326.5 | 350.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -1,978.6 | -961.1 | -1,602.5 | 2,602.4 | 1,058.1 | -822.0 | 336.3 | 361.3 | 388.1 | 416.9 |
| WACC, % | 4.43 | 4.82 | 4.55 | 4.6 | 4.56 | 4.59 | 4.59 | 4.59 | 4.59 | 4.59 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 494.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 425 | |||||||||
| Terminal Value | 16,399 | |||||||||
| Present Terminal Value | 13,100 | |||||||||
| Enterprise Value | 13,595 | |||||||||
| Net Debt | 499 | |||||||||
| Equity Value | 13,097 | |||||||||
| Diluted Shares Outstanding, MM | 2,470 | |||||||||
| Equity Value Per Share | 5.30 |
What You Will Receive
- Authentic 600664 Financial Data: Pre-filled with Harbin Pharmaceutical's historical and projected data for precise analysis.
- Completely Customizable Template: Easily adjust key inputs such as revenue growth, WACC, and EBITDA %.
- Instantaneous Calculations: Observe updates to Harbin Pharmaceutical's intrinsic value in real-time based on your modifications.
- Professional Valuation Tool: Tailored for investors, analysts, and consultants seeking reliable DCF outcomes.
- User-Friendly Layout: Intuitive structure and straightforward instructions suitable for all skill levels.
Key Features
- Accurate Harbin Financials: Gain access to reliable historical data and forward-looking projections for Harbin Pharmaceutical Group Co., Ltd. (600664SS).
- Tailored Forecast Parameters: Modify highlighted fields, such as WACC, growth rates, and profit margins, to match your analysis.
- Responsive Calculations: Enjoy real-time updates for DCF, Net Present Value (NPV), and cash flow evaluations.
- User-Friendly Dashboard: Intuitive charts and summaries to effectively present your valuation findings.
- Suitable for All Skill Levels: Designed with simplicity in mind, catering to investors, CFOs, and consultants alike.
How It Works
- 1. Access the Template: Download and open the Excel file that contains Harbin Pharmaceutical Group Co., Ltd.'s pre-loaded data.
- 2. Modify Assumptions: Adjust key inputs such as growth rates, WACC, and capital expenditures for accurate projections.
- 3. Instantly View Results: The DCF model automatically calculates the intrinsic value and NPV based on your inputs.
- 4. Explore Scenarios: Analyze various forecasts to understand different valuation scenarios.
- 5. Present with Confidence: Utilize professional valuation insights to enhance your decision-making process.
Why Opt for This Calculator?
- User-Friendly and Accessible: Ideal for both newcomers and seasoned professionals.
- Customizable Inputs: Effortlessly adjust parameters to suit your evaluation needs.
- Real-Time Updates: Witness immediate adjustments to Harbin Pharmaceutical Group's valuation as you change inputs.
- Preconfigured Data: Comes equipped with Harbin Pharmaceutical Group’s actual financial figures for fast assessments.
- Relied Upon by Industry Experts: Favored by investors and analysts to make sound decisions.
Who Should Consider This Product?
- Individual Investors: Make well-informed choices regarding the purchase or sale of Harbin Pharmaceutical Group Co., Ltd. (600664SS) stock.
- Financial Analysts: Enhance valuation methodologies with easy-to-use financial models specific to Harbin Pharmaceutical Group Co., Ltd. (600664SS).
- Consultants: Provide accurate and timely valuation insights for clients focusing on Harbin Pharmaceutical Group Co., Ltd. (600664SS).
- Business Owners: Gain insights into how large enterprises like Harbin Pharmaceutical Group Co., Ltd. (600664SS) are valued to inform your own business strategies.
- Finance Students: Acquire practical knowledge of valuation techniques using real-world data from Harbin Pharmaceutical Group Co., Ltd. (600664SS).
Contents of the Template
- Preloaded 600664SS Data: Historical and forecasted financial metrics, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade spreadsheets designed for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for modifying revenue growth, tax rates, and discount rates.
- Financial Statements: Detailed annual and quarterly financial reports for in-depth analysis.
- Key Ratios: Analysis of profitability, leverage, and efficiency ratios to assess performance.
- Dashboard and Charts: Visual representations of valuation outcomes and underlying assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.